Alpha 2.0
Login Register
» Journals » BJC Rep

Bjc Reports

Bjc Reports is a scientific journal, published by Nature Portfolio since 2022 in English. The journal's country of origin is United Kingdom.
Details
Abbr. BJC Rep
Publisher Nature Portfolio
Start 2022
End Continuing
e-ISSN 2731-9377
Country United Kingdom
Language English
Recent Articles
11.
A detoxified TLR4 agonist inhibits tumour growth and lung metastasis of osteosarcoma by promoting CD8+ cytotoxic lymphocyte infiltration
Oyama R, Nabeshima A, Endo M, Novikov A, Fujiwara T, Phelip C, et al.
BJC Rep . 2025 Jan; 3(1):5. PMID: 39870886
Background: Osteosarcoma is the most common malignant bone tumour with limited treatment options and poor outcomes in advanced metastatic cases. Current immunotherapies show limited efficacy, highlighting the need for novel...
12.
Towards greener and more sustainable pre-clinical oncology research
Campion C, Robertson L, Stansfield I, Speirs V
BJC Rep . 2025 Jan; 3(1):4. PMID: 39843971
Single-use plastics (SUPs) are used widely in cancer research laboratories. They are cheap, durable, and lightweight, and until now have been considered disposable items. This, however, contributes significantly to unsustainable...
13.
Targeting the activated allosteric conformation of the endothelin receptor B in melanoma with an antibody-drug conjugate: mechanisms and therapeutic efficacy
Herbet A, Hautiere M, Jean-Alphonse F, Vivier D, Leboeuf C, Costa N, et al.
BJC Rep . 2025 Jan; 3(1):3. PMID: 39833448
Background: Endothelin 1 receptors are one of the drivers of tumor progression in many cancers. Inhibition of their signaling pathways with antagonist drugs has been the subject of numerous clinical...
14.
Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma
Terashima T, Nio K, Koshikawa N, Ueno M, Toyama T, Miyazawa M, et al.
BJC Rep . 2025 Jan; 3(1):2. PMID: 39809945
Background: The identification of effective diagnostic and prognostic biomarkers is critical to improving the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC). We explored the potential of serum levels of...
15.
A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors
Norman A, Seetharam M, Allred J, Kong J, Opyrchal M, Ma W, et al.
BJC Rep . 2025 Jan; 3(1):1. PMID: 39809926
Background: Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine was synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose...
16.
Long term follow-up of women treated for screen detected atypical ductal hyperplasia or lobular neoplasia in a large UK screening centre
Brown N, Pritchard S, Harkness E, Lim Y, Gandhi A, Evans D, et al.
BJC Rep . 2024 Dec; 2(1):90. PMID: 39695332
Background: Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of...
17.
Increased potentiation of 5-fluorouracil induced thymidylate synthase inhibition by 5,10-methylenetetrahydrofolate (arfolitixorin) compared to leucovorin in patients with colorectal liver metastases; The Modelle-001 Trial
Taflin H, Odin E, Carlsson G, Gustavsson B, Hemmingsson O, Wettergren Y, et al.
BJC Rep . 2024 Nov; 2(1):89. PMID: 39567776
Background: 5-Fluorouracil (5-FU) is a cornerstone in treatment of colorectal cancer (CRC) and is usually combined with leucovorin (LV) to enhance the antitumour effect by increase thymidylate synthase (TS) inhibition,...
18.
Single-cell RNA-seq analysis of cancer-endothelial cell interactions in primary tumor and peritoneal metastasis from a single patient with colorectal cancer
Sakimoto Y, Kumegawa K, Matsui S, Yamaguchi T, Mukai T, Okabayashi K, et al.
BJC Rep . 2024 Nov; 2(1):88. PMID: 39558013
Background: Peritoneal metastasis, a major complication of colorectal cancer (CRC), often leads to poor quality of life and unfavorable outcomes. Despite numerous studies characterizing its biological features in CRC, intratumor...
19.
Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer
Bhattarai S, Rupji M, Chao H, Xu Q, Saini G, Rida P, et al.
BJC Rep . 2024 Nov; 2(1):87. PMID: 39537757
Background: Ki67 index (KI) and mitotic index (MI) are proliferation markers with established prognostic value in breast carcinomas. While KI is evaluated immunohistochemically and reported as a percentage, MI is...
20.
Systematic review of risk prediction tools for primary cutaneous melanoma outcomes and validation of sentinel lymph node positivity prediction in a UK tertiary cohort
Manton R, Roshan A
BJC Rep . 2024 Nov; 2(1):86. PMID: 39528626
Background: It is difficult for clinicians to make predictions for cancer progression or outcomes based on AJCC staging for individual patients. Models individualising risk prediction for clinical outcomes are developed...